<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00252577</url>
  </required_header>
  <id_info>
    <org_study_id>MHBA-023-05S</org_study_id>
    <nct_id>NCT00252577</nct_id>
  </id_info>
  <brief_title>Genetic Predictors of Lithium Response in Bipolar Disorder</brief_title>
  <official_title>Genetic Studies of Psychiatric Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify genetic predictors of lithium response in bipolar&#xD;
      disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long term focus of this research program has been identification of genes for bipolar&#xD;
      disorder. The investigators have recently obtained evidence from several lines of&#xD;
      investigation to support the role of the gene for G protein receptor Kinase 3(GRK3) in&#xD;
      bipolar disorder. Work to replicate and extend these results is continuing under NIH funding.&#xD;
      In this clinical the investigators will extend the investigators' work into Pharmacogenetics&#xD;
      to attempt to identify genes that are associated with medication response in bipolar&#xD;
      disorder. Lithium is the first mood stabilizer medication and remains a mainstay of&#xD;
      treatment. Many patients have an excellent response to lithium, tolerate it well, and are&#xD;
      stabilized for years, while others do not. The reasons for this difference in response are&#xD;
      unclear, but it is likely that genetic factors make a substantial contribution. The lack of&#xD;
      good predictors of response frequently result in a time consuming trial and error clinical&#xD;
      process to find the best medication. Such a trial and error process can take months with&#xD;
      prolongation of patient suffering. Hence, there is a strong clinical need for predictors. The&#xD;
      investigators have conducted a preliminary study with 92 lithium responders and 92&#xD;
      non-responders identified through retrospective detailed history and chart review. These&#xD;
      subjects have been genotyped at 88 single nucleotide polymorphism (SNP) markers in 9&#xD;
      candidates genes relevant to lithium presumed mechanism of action for bipolar disorder. Four&#xD;
      SNP markers in three genes showed nominally significant association to lithium response. One&#xD;
      of the SNPs in the gene for neurotrophic receptor tyrosine kinase 2 (NTRK2), the receptor for&#xD;
      brain-derived neurotrophic factor (BDNF), showed a strong association in patients who had&#xD;
      predominantly euphoric a opposed to dysphoric mania (p=0.0005). Many data argue for the role&#xD;
      of BDNF in the mechanism of antidepressants and mood stabilized action as well as&#xD;
      susceptibility to bipolar disorder. No association was observed in those with dysphoric&#xD;
      mania. This suggests that variations in this gene may operate in a clinically and genetically&#xD;
      distinct subset of patients. It also argues for the importance of incorporating clinical&#xD;
      subtypes into such analyses. These pilot results are preliminary but suggest the feasibility&#xD;
      of such an approach. The investigators will conduct a prospective trial of lithium&#xD;
      monotherapy in 100 patients with bipolar disorder. 200 patients who are unstable, mildly to&#xD;
      moderately ill and not on lithium will be screened and then entered into 16-week&#xD;
      stabilization phase where they will be treated and switched to lithium monotherapy. Patient&#xD;
      stable on lithium will also be entered and other mediations withdrawn. After stabilization&#xD;
      patients will be followed for one year or until a mood episode requires intervention. It is&#xD;
      expected that 50% of patients will be stabilized and therefore 100 patients will enter the&#xD;
      maintenance phase. Time to relapse and pharmacological intervention will be the primary&#xD;
      outcome measure. This prospective sample will be used to replicate previous results at the&#xD;
      NTRK2 and other genes. Analyses will be conducted to test for differences in survival curves&#xD;
      between different genotypic group. Genomic control methods will be employed to detect or&#xD;
      correct for possible stratification and heterogeneity. Clinical features of illness such as&#xD;
      dysphoric mania, family history and rapid cycling will be employed as co-variates.&#xD;
      Multivariate methods will also be employed in order to attempt to develop a multi-gene&#xD;
      predictor of lithium response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Relapse</measure>
    <time_frame>every 2 months for 2 years</time_frame>
    <description>The primary outcome measure was time to relapse in months following stabilization on lithium.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">130</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Veterans with bipolar disorder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium treatment</intervention_name>
    <description>Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA from patients with bipolar disorder&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Veterans with bipolar disorder&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are 18 years of age or older;&#xD;
&#xD;
          -  Have a diagnosis of Bipolar Affective Disorder, I or II;&#xD;
&#xD;
          -  Have no contraindications, allergies, or previous adverse events or treatment failures&#xD;
             with lithium;&#xD;
&#xD;
          -  Women who are not currently pregnant and are willing and able to use birth control;&#xD;
&#xD;
          -  Are clinically appropriate to treat with lithium.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  DSM-IV Axis I Diagnosis: other primary comorbid axis I disorders such as:&#xD;
             schizophrenia, schizoaffective disorder, delusional disorder;&#xD;
&#xD;
          -  Alcohol or Substance Dependence: meets criteria for dependence within past 3 months;&#xD;
&#xD;
          -  Unstable Medial Conditions: Life threatening or unstable medical condition that&#xD;
             require active adjustment of medications by medical history; or&#xD;
&#xD;
          -  Medical Conditions: concomitant medical condition that would preclude the use of&#xD;
             lithium (i.e.: renal failure, head trauma with loss of consciousness, or clinically&#xD;
             significant cardiac, renal, hepatic, neoplastic, or cardiovascular disease);&#xD;
&#xD;
          -  Concomitant treatment with the following medications (during maintenance Phase):&#xD;
             antipsychotics, antidepressants, antianxiety agent with the exception of&#xD;
             benzodiazepines, to be used if needed for anxiety or insomnia, not to exceed 10&#xD;
             doses/week, or mood stabilizers with the exception of lithium; and&#xD;
&#xD;
          -  Active suicidal or homicidal ideations as elicited in the interviews.&#xD;
&#xD;
          -  Stable and doing well on a mood stabilizer other than lithium.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John R Kelsoe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA San Diego Healthcare System, San Diego, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA San Diego Healthcare System, San Diego, CA</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.gov/ct2/show/NCT00001174</url>
    <description>NIMH-sponsored study of the genetics of bipolar disorder</description>
  </link>
  <link>
    <url>http://dbsalliance.org</url>
    <description>National Patient support group for bipolar disorder</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 9, 2005</study_first_submitted>
  <study_first_submitted_qc>November 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2005</study_first_posted>
  <results_first_submitted>December 19, 2019</results_first_submitted>
  <results_first_submitted_qc>January 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2020</results_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lithium</keyword>
  <keyword>Pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects with bipolar disorder were recruited through the San Diego VA Mood Clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bipolar Disorder</title>
          <description>Veterans with bipolar disorder&#xD;
Lithium treatment: Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>approximately 80 patients were suitable for analysis once lost to followups and other situations where data was not valid.</population>
      <group_list>
        <group group_id="B1">
          <title>Bipolar Disorder</title>
          <description>Veterans with bipolar disorder&#xD;
Lithium treatment: Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.9" spread="11.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Relapse</title>
        <description>The primary outcome measure was time to relapse in months following stabilization on lithium.</description>
        <time_frame>every 2 months for 2 years</time_frame>
        <population>outpatients at VA San Diego Healthcare System</population>
        <group_list>
          <group group_id="O1">
            <title>Bipolar Disorder</title>
            <description>Veterans with bipolar disorder&#xD;
Lithium treatment: Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse</title>
          <description>The primary outcome measure was time to relapse in months following stabilization on lithium.</description>
          <population>outpatients at VA San Diego Healthcare System</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" lower_limit="19.5" upper_limit="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 years</time_frame>
      <desc>The study is ended.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bipolar Disorder</title>
          <description>Subjects with Bipolar Disorder who are treated with lithium</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>weight gain</sub_title>
                <description>weight gain</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study results are limited by small sample size and a dropout rate higher than expected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John Kelsoe</name_or_title>
      <organization>VA San Diego Healthcare System</organization>
      <phone>858-552-8585 ext 5704</phone>
      <email>john.kelsoe@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

